Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Burlington Stores Fiscal 2025 Q4 Earnings Call - Chose Margin Over Sales Amid Tariffs, Now Bullish on 2026
Burlington leaned into margin preservation in 2025, deliberately dialing down receipt plans in higher-tariff categories to protect profitability. The trade paid off: strong margin expansion and double...
- Q4 headlines: total sales +11% year-over-year, comparable store sales +4%, two-year comp stack +10% for Q4.
- Q4 profitability: adjusted EBIT margin expanded 100 basis points year-over-year; adjusted EPS $4.99, up 21% vs prior year.
- Full-year 2025: total sales +9%, comps +2%, operating margin +80 basis points, adjusted EPS growth +22% year-over-year.
- +13 more takeaways
Amprius Technologies Fourth Quarter 2025 Earnings Call - NDAA-compliant SiCore cells, $125M 2026 guide and a near-term path to positive EBITDA
Amprius closed 2025 with clear commercial momentum and a policy tailwind. Q4 revenue hit a record $25.2 million, full-year revenue was $73 million, and Q4 gross margin improved to 24% as SiCore adopti...
- Q4 2025 revenue: $25.2 million, up 18% quarter-over-quarter and 137% year-over-year; FY2025 revenue: $73 million, roughly 3x 2024.
- Q4 gross margin improved to 24%; full-year gross margin was 11% versus negative 76% in 2024, driven by increased SiCore mix and favorable product mix.
- Management reports full selection of 11 internal cell components from NDAA-compliant countries, claiming a scorecard of 11 out of 11 for country-of-origin requirements.
- +16 more takeaways
Evogene Ltd. Q4 2025 Earnings Call - Strategic pivot to ChemPass AI targeting small-molecule drug and ag-chemical discovery
Evogene used the Q4 2025 call to make the pivot plain. The company has refocused on a single computational engine, ChemPass AI, and narrowed its market targets to human health small-molecule drug disc...
- Company strategic pivot: Evogene has concentrated its R&D and commercial strategy on one computational engine, ChemPass AI, and two markets, human health small-molecule drugs and agricultural chemicals.
- ChemPass AI scale claim: the foundation model was trained or benchmarked on a 38 billion molecule universe and management reported a 90% design precision on internal benchmarks after the first Google Cloud collaboration.
- Google Cloud partnerships: first collaboration completed mid-2025, second collaboration started February 2026 to integrate advanced AI agents via Vertex AI and automate scientific workflows toward autonomous discovery.
- +12 more takeaways
Ultrapar Q4 2025 Earnings Call - Record BRL 5.5bn Operating Cash, Leverage Comfortable at 1.7x
Ultrapar closed 2025 with a headline few companies would ignore, BRL 5.5 billion of operating cash generation, a record that kept leverage comfortable at 1.7 times even after an anticipated BRL 1.1 bi...
- Operating cash generation hit a record BRL 5.5 billion in 2025, the single biggest line in the release and the main driver of financial flexibility.
- Consolidated adjusted EBITDA for Q4 2025 was BRL 1.6 billion, down 34% year-over-year due to non-recurring effects; recurring EBITDA for Q4 was BRL 1.7 billion, up 36% versus Q4 2024.
- For the full year 2025, adjusted EBITDA reached BRL 6.8 billion, up 2% year-over-year; recurring EBITDA totaled BRL 6.2 billion, a 15% increase versus 2024.
- +13 more takeaways
Ciena Fiscal Q1 2026 Earnings Call - Record demand lifts revenue and backlog to $7B, supply to constrain fulfillment into 2027
Ciena reported a blowout fiscal Q1 2026, with record revenue of $1.43 billion, adjusted gross margin of 44.7%, and adjusted EPS of $1.35. Orders were “incredibly strong,” lifting backlog by about $2 b...
- Revenue hit a record $1.43 billion in fiscal Q1 2026, at the top end of guidance, up 33% year-over-year.
- Adjusted gross margin came in at 44.7% for the quarter, ahead of expectations and approaching management’s 45% milestone.
- Adjusted EPS was $1.35, more than double Q1 a year ago, with adjusted net income of $197 million.
- +16 more takeaways
ImmuCell Corporation Q4 2025 Earnings Call - Pivot to First Defense and manufacturing scale lifts margins despite Re-Tain write-downs
ImmuCell closed 2025 with $27.6 million in product sales, a modest full year revenue gain of 4.3% and a clear strategic reset. Management pivoted decisively to the First Defense franchise, resolved a ...
- Company pivoted to focus exclusively on the First Defense franchise and paused investment in the Re-Tain subclinical mastitis program in December 2025.
- Full year product sales were $27.6 million in 2025, up 4.3% versus 2024; Q4 product sales were $7.6 million, down 1.6% year-over-year.
- Domestic Q4 sales rose 8.7% year-over-year to about $7.0 million; international Q4 sales fell to roughly $600,000, about 8% of Q4 sales, primarily due to Canadian order timing.
- +12 more takeaways
Altimmune Q4 2025 Earnings Call - Pemvidutide set for FDA-aligned global 1,800-patient Phase 3 after strong 48-week MASH data
Altimmune entered 2026 with a new CEO and a tight focus on advancing pemvidutide, its dual glucagon/GLP-1 liver-directed candidate. Management reported 48-week Phase 2 MASH data showing early MASH res...
- New CEO Jerry Durso joined in January and is prioritizing pemvidutide as a late-stage, liver-focused program.
- Pemvidutide received FDA Breakthrough Therapy designation in MASH, recognizing preliminary evidence of substantial improvement over available therapies.
- Phase 2 IMPACT data: pemvidutide showed early MASH resolution at 24 weeks and clear anti-fibrotic signals at 48 weeks, with non-invasive tests such as ELF and liver stiffness improving, especially at 1.8 mg.
- +11 more takeaways
Stratasys Q4 2025 Earnings Call - Manufacturing and Aerospace Momentum, but FX and Tariffs Dent Margins
Stratasys closed 2025 showing the strategy is working, even if the macro backdrop is not. The company increased the share of revenue from manufacturing to 37.5% as it converts aerospace, defense, auto...
- Q4 2025 revenue was $140.0 million, down 6.9% year over year; full year revenue was $561.1 million versus $572.5 million in 2024.
- Adjusted EBITDA for Q4 was $9.2 million, a 6.6% EBITDA margin, down from $14.5 million and 9.6% in Q4 2024; full year adjusted EBITDA was $28.5 million, 5.2% of revenue.
- Non-GAAP net income for Q4 was $6.2 million or $0.07 per diluted share; full year non-GAAP net income was $12.7 million or $0.15 per diluted share.
- +12 more takeaways
BJ’s Wholesale Club Fourth Quarter Fiscal 2025 Earnings Call - Membership Surge, Club Buildout and Digital Lift Offset Margin Pressure
BJ’s closed fiscal 2025 with clear momentum, growing members, opening more clubs than ever, and pushing digital penetration higher, all while delivering record full-year EPS. The company added over 50...
- Membership momentum is the headline, with over 500,000 net new members in FY25, total membership topping 8 million, and a rare 90% tenured renewal rate for the fourth consecutive year.
- Management reported record full-year Adjusted EPS of $4.40, and Q4 Adjusted EPS of $0.96, up 3.2% year-over-year, hitting the high end of revised guidance for the year.
- Net sales for Q4 were approximately $5.4 billion, up 5.5% year-over-year; merchandise comparable club sales excluding gasoline rose 2.6% in Q4.
- +12 more takeaways
Lexicon Pharmaceuticals Q4 and Full Year 2025 Earnings Call - Zynquista Resubmission Planned, Multiple Clinical Catalysts in 2026
Lexicon enters 2026 with a clear, catalyst-heavy playbook: a planned NDA resubmission for Zynquista in type 1 diabetes contingent on Steno-1 exposure and DKA safety data, an on-track SONATA-HCM Phase ...
- Company summary: Lexicon is focused on three late-stage assets, sotagliflozin (cardiometabolic, HCM and T1D), pilavapadin (chronic neuropathic pain, Phase 3-ready), and LX9851 (oral obesity program now with Novo Nordisk).
- Zynquista (sotagliflozin in T1D): FDA indicated that Steno-1 investigator-initiated study data may support an NDA resubmission if prespecified patient exposure and DKA safety criteria are met, and Lexicon expects to resubmit in 2026 with a potential approval before year-end.
- Regulatory bar for DKA safety: FDA communicated a target DKA rate comparable to the inTANDEM 400 mg arm, roughly 3.5 cases per 100 patient-years, and Lexicon says current Steno-1 exposure and DKA tracking give them high confidence for submission plans.
- +12 more takeaways